Table 3.
Examples of currently ongoing clinical trials, using CRISPR/Cas9 system for the treatment of cancer (found on ClinicalTrials.gov, acessed on 9 December 2021). [119,120,121,122,123].
| Identifier | Study Title | Start Date | Phase | Disease/Condition |
|---|---|---|---|---|
| NCT05037669 | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma |
January 2022 | I | CD19+ Leukemia and Lymphoma |
| NCT03545815 | Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin- directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors |
19 March 2018 | I | Mesothelin Positive Solid Tumors |
| NCT04976218 | TGF R-KO CAR-EGFR T Cells in Advanced Biliary Tract Cancer |
1 August 2021 | I | Advanced Biliary Tract Cancer |
| NCT04426669 | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering |
15 May 2020 | I/II | Gastrointestinal Cancer |
| NCT03057912 | A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaI |
15 January 2018 | I | Human Papillomavirus- Related Malignant Neoplasm |